Medicinal Chemistry of New Compounds to Treat Tuberculosis

Author(s): Marina Candido Primi, Natanael Dante Segretti, Elizabeth Igne Ferreira

Journal Name: Current Clinical Pharmacology

Volume 10 , Issue 2 , 2015

Become EABM
Become Reviewer


Tuberculosis (TB), a 19th century disease, is still present in the beginning of the Third Millennium. It has been considered pandemic, since around two billion people are infected with M. tuberculosis. Multi-drug resistant TB has been the biggest challenge for chemotherapy. In order to face this severe health problem, many institutions, private and public ones, have been investing in the search for new and better drug candidates. The pipeline of potential anti-TB drugs presents new molecules and formulations that have been submitted to pre-clinical and clinical assays. Medicinal Chemistry has an important role towards the objective of finding new leads through classic and modern processes. This paper reviews some aspects of this search, emphasizing the features of the main compounds under investigation and those that are in preliminary and final clinical trials and includes the contribution of our laboratory (LAPEN) in the area of designing new anti-TB drug candidates.

Keywords: Anti-TB pipelines, designing anti-TB drug candidates, LAPEN contribution, natural products, new anti-TB candidates, new anti-TB leads, tuberculosis.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2015
Page: [139 - 159]
Pages: 21
DOI: 10.2174/1574884708666131229125103
Price: $65

Article Metrics

PDF: 36
PRC: 1